liposomal gemcitabine + pembrolizumab

The combination of liposomal gemcitabine (FF-10832) and pembrolizumab (Keytruda) is an investigational cancer treatment that combines a novel liposomal formulation of gemcitabine with an established immune checkpoint inhibitor[1][2]. This combination therapy has shown promise in clinical trials for treating various advanced solid tumors[1][4]. ## Drug Components Liposomal gemcitabine (FF-10832) is a specialized formulation that encapsulates gemcitabine, an approved anti-cancer agent, in artificially constructed lipid vesicles called liposomes[7][9]. This encapsulation technology aims to enhance the drug's efficacy by: - Prolonging circulation time in the bloodstream - Improving delivery specifically to tumor sites - Potentially overcoming resistance in tumors that don't respond to standard gemcitabine[1] Pembrolizumab (Keytruda) is an established PD-1 immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells[1][2]. ## Clinical Development The combination is being evaluated in clinical trials: - A Phase 2a safety run-in study has been conducted to evaluate tolerability and preliminary efficacy in patients with advanced solid tumors[2][4] - The study included patients with non-small cell lung cancer (NSCLC), urothelial cancer, and renal cell carcinoma[2] - Patients received 200 mg pembrolizumab followed by 40 mg/m² FF-10832 on Day 1 of a 21-day cycle[2] ## Safety Profile The combination therapy has demonstrated a manageable safety profile: - Common adverse events related to FF-10832 included fatigue (50%), anemia (33%), decreased appetite, diarrhea, increased AST, increased alkaline phosphatase, muscular weakness, nausea, and pyrexia (25% each)[2] - Common adverse events related to the combination included fatigue (33%) and nausea (25%)[2] - Three patients experienced Grade ≤2 infusion reactions with the first FF-10832 infusion, but all resolved and were successfully rechallenged[2] ## Mechanism and Technology The liposomal formulation of gemcitabine works through several mechanisms: - Liposomes are artificially constructed lipid vesicles that resemble biological membranes[7] - The encapsulation process uses a pH gradient to induce influx of gemcitabine and lock it in the core as a sulfate complex[6][8] - This approach allows for high drug loading capacity and improved pharmacokinetics[6][8] - Preclinical studies have shown that combining FF-10832 with immune checkpoint inhibitors increased CD8-positive cytotoxic T cells, leading to longer survival compared to monotherapy[9] While this specific combination continues in development, a similar approach combining pembrolizumab with gemcitabine, vinorelbine, and liposomal doxorubicin (pembro-GVD) has shown high efficacy in relapsed/refractory classical Hodgkin lymphoma[3][5].

Brand names

FF-10832 + Keytruda